These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency. AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292 [TBL] [Abstract][Full Text] [Related]
44. Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. Oh JE; Ohta T; Nonoguchi N; Satomi K; Capper D; Pierscianek D; Sure U; Vital A; Paulus W; Mittelbronn M; Antonelli M; Kleihues P; Giangaspero F; Ohgaki H Brain Pathol; 2016 Jul; 26(4):517-22. PubMed ID: 26443480 [TBL] [Abstract][Full Text] [Related]
45. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images. Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242 [TBL] [Abstract][Full Text] [Related]
46. Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype. Dundar B; Alsawas M; Masaadeh A; Conway K; Snow AN; Sompallae RR; Bossler AD; Ma D; Lopes Abath Neto O Pathol Res Pract; 2024 May; 257():155272. PubMed ID: 38631135 [TBL] [Abstract][Full Text] [Related]
47. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526 [TBL] [Abstract][Full Text] [Related]
57. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults. Goodman AL; Velázquez Vega JE; Glenn C; Olson JJ J Neurooncol; 2022 Jun; 158(2):179-224. PubMed ID: 35648306 [TBL] [Abstract][Full Text] [Related]
58. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Tesileanu CMS; Sanson M; Wick W; Brandes AA; Clement PM; Erridge SC; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; van Linde ME; Aldape K; Jenkins RB; Kros JM; Wesseling P; von Deimling A; Hoogstrate Y; de Heer I; Atmodimedjo PN; Dubbink HJ; Brouwer RWW; van IJcken WFJ; Cheung KJ; Golfinopoulos V; Baumert BG; Gorlia T; French PJ; van den Bent MJ Clin Cancer Res; 2022 Jun; 28(12):2527-2535. PubMed ID: 35275197 [TBL] [Abstract][Full Text] [Related]
59. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470 [TBL] [Abstract][Full Text] [Related]
60. O Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]